Multiple Myeloma

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

By

First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.

Feasibility of Clinical Production of Autologous NKG2D CAR-T

Feasibility of Clinical Production of Autologous NKG2D CAR-T

By

The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma

Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma

By

Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Cancer-Related Fatigue May Predict Reduced Survival in Newly Diagnosed Multiple Myeloma

Cancer-Related Fatigue May Predict Reduced Survival in Newly Diagnosed Multiple Myeloma

By

Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.

Measurement of Excess Abdominal Fat, Not BMI, May Be a More Accurate Risk Factor for Blood Cancers

Measurement of Excess Abdominal Fat, Not BMI, May Be a More Accurate Risk Factor for Blood Cancers

By

Abdominal adiposity was determined to be a better predictor of risk for hematological malignancies compared with BMI.

Evaluation of Available Frontline Induction Therapies for Multiple Myeloma

Evaluation of Available Frontline Induction Therapies for Multiple Myeloma

By

There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.

Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?

Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?

By

Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Selinexor and Multiple Myeloma

Selinexor and Multiple Myeloma

By

Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.

Prescription Drug Coverage in Medicare Part D Is Tied to a Survival Advantage in Myeloma

Prescription Drug Coverage in Medicare Part D Is Tied to a Survival Advantage in Myeloma

By

Drug coverage status influenced the treatments that were selected for Medicare beneficiaries with myeloma and, consequently, their overall survival.

Light Therapy May Prevent Depression During Hospitalization Post-Transplant in Multiple Myeloma

Light Therapy May Prevent Depression During Hospitalization Post-Transplant in Multiple Myeloma

By

Previous studies have suggested that light therapy may improve depression by synchronizing patients' circadian rhythm.

Lenalidomide-Based Maintenance Therapy May Be the Most Effective in Myeloma

Lenalidomide-Based Maintenance Therapy May Be the Most Effective in Myeloma

By

Evidence supporting the overall superiority of a single regimen in the maintenance setting in newly diagnosed multiple myeloma is lacking.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

The Multiple Myeloma Pipeline: Therapies to Watch

The Multiple Myeloma Pipeline: Therapies to Watch

By

New approaches in multiple myeloma have the potential to transform the disease into a chronic condition that can be more easily managed.

Real-World Data Support Bortezomib Efficacy in Relapsed/Refractory Multiple Myeloma

Real-World Data Support Bortezomib Efficacy in Relapsed/Refractory Multiple Myeloma

By

Although the effectiveness and safety of bortezomib-based therapy for patients with R/R MM has been demonstrated in phase 2 and phase 3 clinical trials, data collected from real-world settings appear to confirm prior study results.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy

Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy

By

Selecting therapies for patients with multiple myeloma is challenging because the disease is inherently heterogeneous.

Bone Imaging With Improved Modalities in Multiple Myeloma

Bone Imaging With Improved Modalities in Multiple Myeloma

By

Bone imaging is a critical aspect of care for patients with multiple myeloma, and recent advances in imaging modalities have improved detection of lytic lesions and bone marrow involvement—but incorporating these new modalities into clinical practice has been challenging.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Value, Not Cost, Should Be Considered for Myeloma Treatment

Value, Not Cost, Should Be Considered for Myeloma Treatment

By

Even though cancer drugs only account for approximately 1% of the total health care spend, physicians can serve as advocates for patients struggling to afford recommended treatments.

For a Quarter of Myeloma Patients, Diagnosis Can Take 3 Months or More

For a Quarter of Myeloma Patients, Diagnosis Can Take 3 Months or More

By

Repeat primary care consultations before a diagnosis was assigned and non-specific symptoms were two factors that caused delays in the diagnosis of patients with myeloma following the appearance of symptoms.

Global Burden of Myeloma Increasing, Access to Treatments Lacking

Global Burden of Myeloma Increasing, Access to Treatments Lacking

By

A new study reveals that an aging world population is the predominant contributor to a 126% increase in age-standardized incidence rates of multiple myeloma from 1990 to 2016.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

Early Results Suggest That Once-Weekly, High-Dose Carfilzomib Prolongs PFS in Multiple Myeloma

By

In the phase 3 ARROW study patients with relapsed/refractory multiple myeloma were randomly assigned to receive carfilzomib 27 mg/m2 twice-weekly or 70 mg/m2 once-weekly

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma

By

The increase in use of lenalidomide as maintenance treatment emphasizes the need to explore additional treatment options among patients with lenalidomide-refractory multiple myeloma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs